• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Guilherme Rabinowits, MD


  • Thakuria M, LeBoeuf NR, Rabinowits G.Update on the biology and clinical management of merkel cell carcinoma.Am Soc Clin Oncol Educ Book. 2014;34:e405-10.
  • Rabinowits G.Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?.Cancers (Basel). 2014;6(2):1180-94.
  • Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M.Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.Lancet Oncol. 2013 Mar;14(3):257-64.
  • Keung EZ, Liu X, Nuzhad A, Rabinowits G, Patel V.In-hospital and long-term outcomes after percutaneous endoscopic gastrostomy in patients with malignancy.J Am Coll Surg. 2012 Dec;215(6):777-86.
  • Rabinowits G, Haddad RI.Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature.Oral Oncol. 2012 Nov;48(11):1085-9.
  • Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA.Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.Am J Med Sci. 2010 Feb;339(2):148-51.
  • Rabinowits G, Laber DA.Bladder cancer: clinical practice.J Ky Med Assoc. 2009 Apr;107(4):129-33. Review.
  • Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH.Exosomal microRNA: a diagnostic marker for lung cancer.Clin Lung Cancer. 2009 Jan;10(1):42-6.
  • Rabinowits G, Shuster TD, Pazianos AG, Laber DA.Indolent course of thymic carcinoid.J Clin Oncol. 2007 Mar 20;25(9):1138-9.
  • Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W.Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.Anti Cancer Drugs. 2003 Sep;14(8):665-8.